The 7 major age-related macular degeneration markets reached a value of US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12.0 Billion by 2034, exhibiting a growth rate (CAGR) of 1.54% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2023
|
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 10.1 Billion
|
Market Forecast in 2034
|
US$ 12.0 Billion
|
Market Growth Rate 2024-2034
|
1.54% |
The age-related macular degeneration market has been comprehensively analyzed in IMARC's new report titled "Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Age-related macular degeneration (AMD) refers to an acquired eye disease that primarily affects older adults. The illness specifically damages the macula, which is the central part of the retina responsible for sharp and central vision. There are two main types of this ailment: dry and wet. Dry AMD progresses slowly and may result in mild to moderate vision loss, whereas wet AMD can cause sudden and severe central vision impairment. Individuals suffering from the disease may experience difficulty recognizing faces, problems with reading, blurred or distorted central vision, dark or empty areas in the center of the visual field, etc. The diagnosis of this condition typically requires a review of the patient's medical history, underlying symptoms, and ophthalmic examination. During a dilated eye exam, the healthcare provider will examine the macula to check for any abnormalities, such as drusen (yellow deposits) and pigment changes, which are indicative of AMD. Numerous other diagnostic procedures, including optical coherence tomography and indocyanine green angiography, are also utilized to confirm a diagnosis among patients.
The expanding geriatric population, who are prone to the degradation of macula cells due to structural and blood flow changes, is primarily driving the age-related macular degeneration market. Additionally, the increasing prevalence of several associated risk factors, such as genetic predisposition, high blood pressure, smoking, prolonged exposure to blue light, obesity, consumption of a diet rich in saturated fat, etc., is also propelling the market growth. Moreover, the widespread demand for vascular endothelial growth factor inhibitors, which are injected directly into the eye to reduce abnormal blood vessels, is further creating a positive outlook for the market. Besides this, the escalating adoption of laser photocoagulation for treating AMD, since it helps to alleviate the symptoms and slow down the progression of the ailment in patients, is also acting as another significant growth-inducing factor. Additionally, the rising utilization of retinal gene therapy, owing to its various advantages, including long-lasting effects, reduced treatment frequency, and enhanced quality of life for individuals suffering from this condition, is expected to drive the age-related macular degeneration market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the age-related macular degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for age-related macular degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the age-related macular degeneration market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current age-related macular degeneration marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Beovu (Brolucizumab) | Novartis |
SusvimoTM (Ranibizumab) | Genentech/Novartis Ophthalmics |
Vabysmo (Faricimab) | Roche |
Lucentis (Ranibizumab) | Genentech/Novartis Ophthalmics |
Eylea (Aflibercept) | Bayer/Regeneron Pharmaceuticals/Sanofi |
KSI-301 | Kodiak Sciences |
RGX-314 | REGENXBIO |
Risuteganib | Allegro Ophthalmics |
OPT302 | Opthea |
PAN90806 | PanOptica |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Age-Related Macular Degeneration: Current Treatment Scenario, Marketed Drugs and Emerging Therapies